14Jul
Japan Tightens Foreign Direct Investment Regulations on Life Science Companies - Prior notification requirements under the Japanese regulations were expanded to cover investments in life science companies.
On June 15, 2020, the Japanese government implemented new regulations that designate the manufacture of pharmaceuticals for infectious diseases and the manufacture of highly-controlled medical devices (medical devices that are classified as Class III or Class IV in Japan, such as a heart–lung machines and ventilators) as both "Designated Businesses" and "Core Businesses" under the Foreign Exchange and Foreign Trade Act of Japan ("FEFTA"). The new regulations were adopted in light of the COVID-19...
By:
Jones Day
Related
Seyfarth Synopsis: The hotly contested AB 5 was put on hold, but is widely expected to be revived be...
Read More >
In Appeal of Watts Constructors, LLC, the Armed Services Board of Contract Appeals (the “Board”) h...
Read More >
Seyfarth Synopsis: The U.S. Supreme Court upheld this week a key component of administrative law tha...
Read More >
Given that the gig economy is a relatively recent phenomenon, the industry has not yet experienced s...
Read More >
AB 51 was signed into law on October 10, 2019, and purported to outlaw the use of mandatory arbitrat...
Read More >
Be a part of the conversation! Join us for our International Women's Day event, a solutions-oriented...
Read More >